Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Directors' Dealing

1 Feb 2018 09:39

RNS Number : 6200D
Ergomed plc
01 February 2018
 

Ergomed Plc

("Ergomed" or the "Company")

 

Directors' Dealing

 

Ergomed, a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that on 1 February 2018, Mr Peter George, Chairman of the Company, bought 500,000 ordinary shares of 1p each in the Company ("Share(s)") at a price of 190p per Share from Dr Miroslav Reljanovic, founder and Executive Vice-Chairman of the Company. Separately, in response to excess demand from the placing announced by the Company this morning, Dr Miroslav Reljanovic sold an additional 2,000,000 Shares at a price of 190p.

 

Following these transactions, Mr Peter George holds 776,250 shares (representing 1.8 per cent. of the Company's issued share capital and 1.7 per cent. of the Company's issued share capital following admission of the Placing Shares relating to the Placing announced by the Company earlier this morning) and Dr Miroslav Reljanovic's holding has reduced to 15,132,237 shares (representing 35.5 per cent. of the Company's issued share capital and 33.8 per cent. of the Company's issued share capital following admission of the Placing Shares relating to the Placing announced by the Company earlier this morning).

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1) Peter George

2) Dr Miroslav Reljanovic

2

Reason for the notification

a)

Position/status

1) Chairman

2) Founder and Executive Vice-Chairman

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed Plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 GB00BN7ZCY67

b)

Nature of the transaction

1) Purchase of shares

2) Sale of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

190p

500,000

190p

2,500,000

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

1) 500,000

2) 2,500,000

 

1) 190p

2) 190p

 

1) £950,000.00

2) £4,750,000.00

f)

Date of the transaction

1 February 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEANAFEDSPEEF
Date   Source Headline
26th Apr 20189:58 amRNSIssue of shares and PDMR
17th Apr 20185:47 pmRNSHoldings in Company
16th Apr 20183:55 pmRNSDirectors' Dealing
11th Apr 20187:00 amRNSPreliminary Results
9th Apr 20186:26 pmRNSHolding(s) in Company
20th Mar 20187:00 amRNSNotice of Preliminary Results: Date Change
5th Mar 20187:00 amRNSTrading Update & Notice of Results
21st Feb 20182:35 pmRNSHoldings in Company
6th Feb 20182:03 pmRNSHoldings in Company
5th Feb 20185:07 pmRNSHoldings in Company
1st Feb 20189:39 amRNSDirectors' Dealing
1st Feb 20187:00 amRNSCompletion of Placing
25th Jan 20187:00 amRNSErgomed 2017 Trading Update
10th Jan 20181:00 pmRNSHoldings in Company
15th Dec 20177:00 amRNSBoard changes
12th Dec 20177:00 amRNSCo-dev partnership with Allergy Therapeutics
4th Dec 20177:00 amRNSErgomed's PrimeVigilance hosts automation seminar
27th Nov 20177:00 amRNSErgomed to present at the German Equity Forum 2017
23rd Oct 20177:00 amRNSErgomed's PeproStat reports positive results
12th Oct 20174:48 pmRNSHolding(s) in Company
3rd Oct 20177:00 amRNSCompletion of Acquisition of PSR Group BV
28th Sep 201710:46 amRNSResult of Placing
28th Sep 20177:02 amRNSAcquisition of PSR Group BV and Placing
27th Sep 20177:00 amRNSCommercialisation Deal on Haemostatix Products
18th Sep 20177:00 amRNSInterim Results
21st Aug 20177:06 amRNSCEL-SCI Corporation issues restricted shares
14th Aug 201712:31 pmRNSFDA removal of hold on Ph3 trial with Multikine
14th Aug 20177:00 amRNSNotice of Results
24th Jul 20177:00 amRNSRecruitment complete early for Phase IIb study
4th Jul 201712:30 pmRNSInvestor Meeting
21st Jun 20177:00 amRNSPeproStat study passes recruitment mid-point
16th Jun 20175:44 pmRNSResult of AGM
16th Jun 20177:00 amRNSAppointment of CEO
22nd May 20177:00 amRNSAppointment of N+1 Singer as joint broker
12th May 20174:54 pmRNSAnnual Report and Notice of AGM
8th May 201712:00 pmRNSIssue of Shares to Former PharmInvent Shareholders
2nd May 20177:00 amRNSCo-Development Partner News
13th Apr 20177:00 amRNSBoard and Management Changes
4th Apr 201710:50 amRNSDirector/PDMR Shareholding
3rd Apr 20177:00 amRNSPartner Asarina Pharma announces successful data
28th Mar 20177:00 amRNSUnaudited Preliminary Results for 2016
21st Mar 20177:00 amRNSNotice of Preliminary Results
20th Mar 20177:00 amRNSInitiates Phase II Study of Topical PeproStat
20th Feb 20177:00 amRNSModus Therapeutics Raises SEK 32 Million
6th Feb 20177:02 amRNSPositive Phase II top-line results of Lorediplon
31st Jan 20174:00 pmRNSCompletion of ZoptrexT Phase 3 Clinical Trial
17th Jan 20177:00 amRNSTrading Statement
30th Nov 20164:35 pmRNSAward of Options by CEO to CFO and General Counsel
29th Nov 20167:00 amRNSAcquisition of PharmInvent
21st Nov 20167:00 amRNSProposed Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.